Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
Not Applicable
Completed
- Conditions
- Pancreatic Tumor
- Interventions
- Procedure: suspected pancreatic tumor
- Registration Number
- NCT01692873
- Lead Sponsor
- Institut Paoli-Calmettes
- Brief Summary
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat.
Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response.
This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 274
Inclusion Criteria
- Suspicion of pancreatic adenocarcinoma
- Patient > 18 years old
- Social Security affiliation
- Signed informed consent
Exclusion Criteria
- Patient in emergency situation
- Major person being the object of a legal protective measure or unable to express its consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description suspected pancreatic tumor suspected pancreatic tumor Realization of pancreatic tumor biopsy and blood samples
- Primary Outcome Measures
Name Time Method Biomarkers within twenty four hours Genomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkers
- Secondary Outcome Measures
Name Time Method Histology within twenty four hours To determine the histologic characteristics of the pancreatic tumor
Trial Locations
- Locations (1)
Marine GILABERT, MD
🇫🇷Marseille, France